Document is current
Any future updates will be listed below
-
Authors
Newton, Lydia S. https://orcid.org/0009-0002-1706-8346
Gathmann, Clara
Ridewood, Sophie
Smith, Robert J. https://orcid.org/0000-0002-0003-7132
Wijaya, Andre J. https://orcid.org/0009-0006-0378-376X
Hornsby, Thomas W.
Morling, Kate L. https://orcid.org/0000-0002-2343-3410
Annett, Dara
Chiozzi, Riccardo Zenezini https://orcid.org/0000-0003-3904-5532
Reuschl, Ann-Kathrin https://orcid.org/0000-0002-1459-3519
Govasli, Morten L.
Tan, Ying Ying
Thorne, Lucy G. https://orcid.org/0000-0001-7358-6047
Jolly, Clare https://orcid.org/0000-0002-4603-2281
Thalassinos, Konstantinos https://orcid.org/0000-0001-5072-8428
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Towers, Greg J. https://orcid.org/0000-0002-7707-0264
Selwood, David L. https://orcid.org/0000-0002-6817-5064
-
Funding
Funding for this research was provided by:
Wellcome Trust (214344, 204841/Z/16/Z)
Rosetrees Trust (ID2020/100020)
- License Information
-
More Information
Article History
Received: 28 February 2023
Accepted: 14 January 2025
First Online: 10 February 2025
Competing interests
: The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KGaA, Nurix Therapeutics, Ono Pharmaceutical and Tocris-BioTechne. A.C. is a scientific founder, advisor, and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The other authors declare no competing interests.
